News story

Latest topics referred to NICE: July 2011

This news article was published under the 2010 to 2015 Conservative and Liberal Democrat coalition government

Department of Health ministers agreed to refer the following topics to the National Institute for Health and Clinical Excellence (NICE).

Department of Health ministers agreed to refer the following topics to the National Institute for Health and Clinical Excellence (NICE) in July, to begin the process of developing guidance for each topic.

Social care

Ministers agreed that NICE should take forward work in partnership with the Social Care Institute for Excellence to pilot arrangements for the development of two statements of standards spanning both NHS and social care pathways. These are:

  • health and well-being of looked after children
  • care of the elderly mentally ill in a residential setting

Public health

These are the public health topics that have been referred to NICE.

  • Managing overweight and obesity in children: lifestyle weight management services
  • Assessing BMI and waist circumference in adults in black and minority ethnic (BME) groups in the UK

Find out more about NICE public health guidance on the NICE website.

Technology appraisals

These are the technology appraisals that have been referred to NICE.

  • To appraise the clinical and cost effectiveness of botulinum toxin type A within its licensed indication for the prophylaxis of headaches associated with chronic migraine.
  • To appraise the clinical and cost effectiveness of lenalidomide within its licensed indication for the maintenance treatment of multiple myeloma after autologous stem cell transplantation.
  • To appraise the clinical and cost effectiveness of lenalidomide within its licensed indications: induction therapy for newly diagnosed multiple myeloma and as maintenance therapy for newly diagnosed multiple myeloma in people who have previously received induction chemotherapy.
  • To appraise the clinical and cost effectiveness of lenalidomide within its licensed indication for the treatment of myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality in people with red blood cell transfusion dependence.
  • To appraise the clinical and cost effectiveness of erlotinib, within its licensed indication, for the first-line treatment of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) mutation positive locally advanced or metastatic non-small-cell lung cancer.

Find out more about NICE technology appraisals on the NICE website.**

About NICE referrals

NICE](http://www.nice.org.uk/) is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health.

Department of Health ministers refer topics to NICE and NICE schedules these topics into its work programme, to begin the process of developing guidance for each topic.

Depending on the type of guidance and its complexity, this can take between 6 months and 2 years.

NICE guidance includes technology appraisals, clinical guidelines, public health guidelines and quality standards.

Find out more about NICE guidance on the NICE website.